Movement Alert｜CSPC PHARMA Rises 4.43% in Regular Trading, AstraZeneca Collaboration Deepens with Milestone Payment and Joint Venture

Market Focus08-10

On August 10, CSPC PHARMA rose 4.43% in regular trading, trading at HK$8.98 per share, with turnover of HK$76.02 million. The rally was driven by a cluster of positive developments centered on its deepening strategic partnership with AstraZeneca.

On August 5, CSPC PHARMA announced it received a US$10 million milestone payment from AstraZeneca following the exercise of a license option for one pre-clinical candidate program under their strategic R&D collaboration agreement originally disclosed in June 2025. The same day, the two parties signed a joint venture contract to establish a new-generation biologics manufacturing facility in Shijiazhuang, China, with CSPC holding 51% and AstraZeneca holding 49%. Additionally, on August 4, the company's co-developed anituomab plus docetaxel neoadjuvant therapy new drug application was accepted by China's NMPA and granted priority review status.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155141178?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 09:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155141178","market":"us","top_or_hot":-1,"title":"Movement Alert｜CSPC PHARMA Rises 4.43% in Regular Trading, AstraZeneca Collaboration Deepens with Milestone Payment and Joint Venture","media":"Market Focus","content":"<p><p>On August 10, CSPC PHARMA rose 4.43% in regular trading, trading at HK$8.98 per share, with turnover of HK$76.02 million. The rally was driven by a cluster of positive developments centered on its deepening strategic partnership with AstraZeneca.</p><p>On August 5, CSPC PHARMA announced it received a US$10 million milestone payment from AstraZeneca following the exercise of a license option for one pre-clinical candidate program under their strategic R&D collaboration agreement originally disclosed in June 2025. The same day, the two parties signed a joint venture contract to establish a new-generation biologics manufacturing facility in Shijiazhuang, China, with CSPC holding 51% and AstraZeneca holding 49%. Additionally, on August 4, the company's co-developed anituomab plus docetaxel neoadjuvant therapy new drug application was accepted by China's NMPA and granted priority review status.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CSPC PHARMA Rises 4.43% in Regular Trading, AstraZeneca Collaboration Deepens with Milestone Payment and Joint Venture</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CSPC PHARMA Rises 4.43% in Regular Trading, AstraZeneca Collaboration Deepens with Milestone Payment and Joint Venture\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-10 09:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 10, CSPC PHARMA rose 4.43% in regular trading, trading at HK$8.98 per share, with turnover of HK$76.02 million. The rally was driven by a cluster of positive developments centered on its deepening strategic partnership with AstraZeneca.</p><p>On August 5, CSPC PHARMA announced it received a US$10 million milestone payment from AstraZeneca following the exercise of a license option for one pre-clinical candidate program under their strategic R&D collaboration agreement originally disclosed in June 2025. The same day, the two parties signed a joint venture contract to establish a new-generation biologics manufacturing facility in Shijiazhuang, China, with CSPC holding 51% and AstraZeneca holding 49%. Additionally, on August 4, the company's co-developed anituomab plus docetaxel neoadjuvant therapy new drug application was accepted by China's NMPA and granted priority review status.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1155141178","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155141178","pubTimestamp":1786325494,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 10, CSPC PHARMA rose 4.43% in regular trading, trading at HK$8.98 per share, with turnover of HK$76.02 million. The rally was driven by a cluster of positive developments centered on its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"走势提醒|石药集团常规交易上涨4.43%，阿斯利康通过里程碑支付和合资企业深化合作","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"On August 10, CSPC PHARMA rose 4.43% in regular trading, trading at HK$8.98 per share, with turnover of HK$76.02 million. The rally was driven by a cluster of positive developments centered on its deepening strategic partnership with AstraZeneca.On August 5, CSPC PHARMA announced it received a US$10 million milestone payment from AstraZeneca following the exercise of a license option for one pre-clinical candidate program under their strategic R&D collaboration agreement originally disclosed in June 2025. The same day, the two parties signed a joint venture contract to establish a new-generation biologics manufacturing facility in Shijiazhuang, China, with CSPC holding 51% and AstraZeneca holding 49%. Additionally, on August 4, the company's co-developed anituomab plus docetaxel neoadjuvant therapy new drug application was accepted by China's NMPA and granted priority review status.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155141178","isCrawlerRequest":true}